- Home
- NGNE vs OABI Comparison
NGNE vs OABI Comparison
Compare NGNE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OABI
- Stock Information
- Founded
- NGNE 2003
- OABI 2012
- Country
- NGNE United States
- OABI United States
- Employees
- NGNE N/A
- OABI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- OABI Health Care
- Exchange
- NGNE Nasdaq
- OABI Nasdaq
- Market Cap
- NGNE 352.4M
- OABI 388.5M
- IPO Year
- NGNE N/A
- OABI N/A
- Fundamental
- Price
- NGNE $16.62
- OABI $3.22
- Analyst Decision
- NGNE Strong Buy
- OABI Strong Buy
- Analyst Count
- NGNE 6
- OABI 4
- Target Price
- NGNE $60.80
- OABI $9.00
- AVG Volume (30 Days)
- NGNE 223.3K
- OABI 448.8K
- Earning Date
- NGNE 11-18-2024
- OABI 11-12-2024
- Dividend Yield
- NGNE N/A
- OABI N/A
- EPS Growth
- NGNE N/A
- OABI N/A
- EPS
- NGNE N/A
- OABI N/A
- Revenue
- NGNE $925,000.00
- OABI $20,409,000.00
- Revenue This Year
- NGNE N/A
- OABI N/A
- Revenue Next Year
- NGNE N/A
- OABI $78.61
- P/E Ratio
- NGNE N/A
- OABI N/A
- Revenue Growth
- NGNE N/A
- OABI N/A
- 52 Week Low
- NGNE $14.44
- OABI $3.16
- 52 Week High
- NGNE $74.49
- OABI $6.55
- Technical
- Relative Strength Index (RSI)
- NGNE 29.82
- OABI 32.70
- Support Level
- NGNE $17.63
- OABI $3.16
- Resistance Level
- NGNE $20.29
- OABI $3.29
- Average True Range (ATR)
- NGNE 1.49
- OABI 0.13
- MACD
- NGNE -0.17
- OABI -0.02
- Stochastic Oscillator
- NGNE 7.29
- OABI 9.09
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.